Supplementary Information

Impairment of T cells' antiviral and anti-inflammation immunities dominates the death from COVID-19

Luhao Zhang[1,2]†, Rong Li[1,3]†, Gang Song[4], Gregory D. Scholes[2]* and Zhen-Su She[1,3]*

[1]Institute of Health System Engineering, College of Engineering, Peking University, Beijing, China, 100871.

[2]Department of Chemistry, Princeton University, Princeton, NJ, 08540.

[3]State Key Laboratory for Turbulence and Complex Systems, Peking University, Beijing, China, 100871.

[4]Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China, 100730

†These authors contribute equally

*Corresponding author: Gregory D. Scholes, 609-258-0729, gscholes@princeton.edu, 125, Frick Laboratory, Department of Chemistry, Princeton University, Princeton, NJ, and Zhen-Su She, 010-62766559, she@pku.edu.cn, 206, Peking University State Key Laboratory of Turbulence and Complex Systems, Beijing, China.

This file includes:

Supplementary text
Figures S1
Tables S1 to S8
SI References

Supplementary Information Text

- **Parameter fixed during the fitting**

For all the fits, A_0 is fixed to be cut-off values or to estimated values based on the data points before the rise. T_0 is fixed at the maximum of data. N is selected to be -5 or -10 according to different viral load profiles. I_0 was estimated by taking an average of the first three data points. For both survivors and non-survivors, S_{d0} was set to be 0.25 (half of the normal range), S_{h0} was set to be 0. ϵ and θ are the decay rates and were gained by linear regression of the decay profiles. For cases without decay data points, the fitted ϵ values of other patients with the same severity were used, while an average of the fitted θ (P1, P3, 902, 916) 0.036 is used. For 910 patient and non-survivors who is lack of saturated points for antibodies, only γ and τ were varied. κ for survivors is allowed to vary when data of IL-6 is varied.

- **Estimation of uncertainty of parameters related with antiviral dynamics**

For antiviral dynamics, large fluctuated points of virus, T cells, or antibodies were added in one by one (with an order along days after symptom onset), each time with a fit to get a set of parameters. Large fluctuated points have slope with its neighbor point around or larger than three times the slope of other nearby points. The fitting process is repeated until all the fluctuated points are added. If more than one data type has fluctuated points, we used all the possible combinations. If the fit became second positive, it was abandoned. All the fits gave the minimum (lower bound, LB) and maximum (upper bound, UB) for each parameter, used as the lower and upper bound of uncertainty for each parameter, see Table S4. For T_0, the 95%CI of the maximum data point was used as its uncertainty. For ϵ and θ, 95%CI of fitting of the decay profiles were used for uncertainty. If the data of a certain case is not enough for estimating the uncertainty of T_0, ϵ, or θ, the uncertainty was estimated by that of the corresponding group with the same severity. If the average value of θ was applied to a certain case, 95%CI of 916 was used for the uncertainty because it covers all other individual's θ. 95%CI of 916 is also used for estimation of other patients'θ that is calculated by only two points in the antibody decay profile. N was initially fixed and have no uncertainty. A_0's uncertainty is supposed to be determined by instrumental error and was not estimated from the limited number of data points before rising.



Fig.S1 Comparison of simulation to data for dynamics of virus (circle), T cells (square), and neutralizing antibodies (triangle). a-e are mild individuals and group, plotted in blue. f-i are severe(critical) individuals and group, plotted in green.

Table S1 Parameters of the Antiviral-Inflammation Model and their units.

Parameter	Description	Unit
Antiviral parameters		
V_0	Initial viral load	copy/mL
T_0	Initial naïve T cell concentration	10^9cell/L
A_0	Initial antibody concentration	OD, or OD Ratio, or Titer
N	Starting day for simulation	Days after symptom onset
$\tilde{\alpha}$	Virus replication rate	Day^{-1}
β	Virus killing rate per unit T cells	(10^9cell/L)$^{-1}$ Day^{-1}
γ	Virus killing rate by per unit antibodies	(OD, or OD Ratio, or Titer)$^{-1}$ Day^{-1}
δ	T cell activation rate per unit virus	(copy/mL)$^{-1}$(10^9cell/L) Day^{-1}
ϵ	T cell decay rate	Day^{-1}
η	Antibody secretion rate per unit virus	(copy/mL)$^{-1}$(OD, or OD Ratio, or Titer) Day^{-1}
τ	Preparation time before antibody secretion begins	Day
θ	Antibody decay rate	Day^{-1}
Inflammation parameters		
I_0	Initial concentration of IL-6	pg/mL
S_{d0}	Initial concentration of d-dimer	μg/mL
S_{h0}	Initial concentration of high-sensitivity cardiac troponin I	ng/mL
κ	IL-6 formation rate	(OD, or OD Ratio, or Titer)$^{-1}$ (pg/mL) Day^{-1}
λ	IL-6 inhibition rate	Day^{-1}
μ_d	Formation rate of d-dimer	(pg/mL)$^{-1}$(μg/mL) Day^{-1}
ν_d	Inhibition rate of d-dimer	Day^{-1}
μ_h	Formation rate of high-sensitivity cardiac troponin I	(pg/mL)$^{-1}$(ng/mL) Day^{-1}
ν_h	Inhibition rate of high-sensitivity cardiac troponin I	Day^{-1}

Table S2 Populations of virus, T cell, and antibody data sources that are integrated for mild, severe (critical) and non-survivor group.

	Virus	T cell	Antibody
Mild	38 individuals from Guohong Deng[1]' s nasopharyngeal swab data from non-severe group.	138 individuals from Hongzhou Lu[2]'s CD3+ count.	22 individuals from Guohong Deng's Anti-NP IgG data for non-severe group.
Severe (critical)	20 severe + 9 critical individuals from Guohong Deng's nasopharyngeal swab data from severe group.	12 severe and 16 critical individuals from Hongzhou Lu's CD3+ count. Take the weighted average of severe and critical medians according to 20:9, so as the estimation of error bars.	23 individuals from Guohong Deng's Anti-NP IgG from severe group.
Non-survivors	2 individuals from Kelvin To[3]'s saliva data and Yazdan Yazdanpanah[4]'s nasopharyngeal data.	54 individuals from BinCao[5]'s Lymphocyte count.	Use one of the 2 patients to represent the two with viral load data.

Table S3 Indices of data points of virus, T cells, and antibodies used for performing best fits of each case.

Patient ID follows the Latin letter of their corresponding panel in Supplementary Fig 1 and Fig.2. For group data, best fits were performed using median values. "Total" means all the data were used. "-" means the data were not used. For fits of I, S_d, and S_h, all the data were used.

Patient ID	*V* data	*T* data	*A* data
a:908	[1,4,11,13,14,15,16:19,21,22]	Total	Total
b:904	[1,4,5,9:12]	Total	Total
c:901	[1,2,4,7,11,14,17,24]	Total	Total
f:902	[1:7]	[1:16]	Total
g:910	[1,5,12,13]	[1:16]	Total
h:916	[1,3,5:6]	Total	Total
2a:P1	[1:4,5:7]	Total	[2:5]
2b:P3	[1:2,4:8]	Total	[1,3,4,6,8,9]
d:P4	[1:7]	[1,5,7]	Total
2c:P5	[4:8]	[1,3,5,6]	Total
Survivors	[1:6,8:10,12,14:16,17:19,21:23]	Total	[1:21,25]
Non-survivors	[1:8]	-	Total
e:Mild group	[1:7]	Total	[1:4,6,10,11]
i:Severe group	[1:2,4,6:8]	Total	[1:10,12]

Table S4 Best fit (with estimated parameter uncertainty) to each patient (group).

LB: Lower bound of the uncertainty. UB: Upper bound of the uncertainty. "-" means the parameter is either during uncertainty estimation or the quality of data is not able to perform the estimation. Patient f:902 has no reasonable fitting other than best fit.

Patient ID	$\tilde{\alpha}$	$log10(V_0)$	β	γ	$\delta/10^{-8}$	$\epsilon/10^{-1}$	$\eta/10^{-8}$	τ	$\theta/10^{-2}$	T_0	A_0	N
a:908	0.51	6.47	1.18	0.65	0.22	1.14	0.44	11.70	3.57	1.45	0.11	-10
LB	0.48	5.45	1.12	0.50	0.22	1.06	0.44	11.70	0	1.09	-	-
UB	0.52	6.47	1.21	0.65	2.35	1.22	4.87	12.36	10.99	1.81	-	-
b:904	0.89	5.98	2.08	1.21	0.02	1.14	0.04	14.09	3.57	1.45	0.08	-10
LB	0.82	4.31	1.93	0.88	0.02	1.06	0.04	13.90	0	1.09	-	-
UB	1.09	5.98	2.50	1.21	0.37	1.22	0.65	14.56	10.99	1.81	-	-
c:901	0.47	4.62	1.15	0.54	34.92	1.14	68.40	17.18	3.57	1.45	0.06	-10
LB	0.47	4.24	1.15	0.54	30.48	1.06	64.64	17.18	0	1.09	-	-
UB	0.59	4.62	1.44	0.64	34.92	1.22	68.40	18.43	10.99	1.81	-	-
f:902	0.58	3.69	1.70	1.19	1.81	1.40	4.48	5.40	5.11	1.06	0.11	-10
LB	-	-	-	-	-	1.17	-	-	0	0.68	-	-

UB	-	-	-	-	-	1.64	-	-	10.99	1.44	-	-
g:916	0.41	6.12	1.93	1.44	0.09	0.33	0.43	12.79	5.49	0.64	0.11	-10
LB	0.33	5.27	1.50	0.10	0.06	0.22	0.28	12.79	0	0.39	-	-
UB	0.46	6.66	2.28	1.75	0.65	0.44	3.28	13.83	10.99	0.89	-	-
h:910	0.70	2.00	3.00	3.36	0.15	1.40	0.40	7.74	3.57	1.06	0.08	-10
LB	-	-	-	2.52	-	1.17	0.40	7.74	0	0.68	-	-
UB	-	-	-	4.68	-	1.64	2.08	10.80	10.99	1.44	-	-
	$\tilde{\alpha}$	$log10(V_0)$	β	γ	$\delta/10^{-8}$	$\epsilon/10^{-1}$	$\eta/10^{-8}$	τ	$\theta/10^{-2}$	T_0	A_0	N
2a:P1	1.17	2.93	10.00	1.52	0.50	1.14	14.58	11.22	1.65	1.74	0.30	-5
LB	0.79	2.93	7.18	1.52	0.07	1.06	1.91	11.02	0	1.53	-	-
UB	1.17	7.70	10.00	2.58	0.57	1.22	14.58	18.62	10.99	1.95	-	-
2b:P3	1.48	6.63	8.05	4.72	0.01	0.78	0.02	20.13	2.03	0.90	0.16	-10
LB	1.30	6.61	8.05	4.72	0.01	0.76	0.02	20.10	0	0.69	-	-
UB	1.48	7.01	8.82	4.91	0.01	0.80	0.03	20.48	10.99	1.11	-	-
d:P4	1.86	4.00	3.84	47.30	2.38	4.14	7.84	8.45	3.57	1.11	0.42	-5

LB	1.83	3.69	3.84	43.57	1.65	4.11	7.56	8.45	0	0.90	-	-
UB	2.11	4.29	7.02	49.25	2.38	5.01	8.83	8.83	10.99	1.32	-	-
2c:P5	0.82	4.69	1.31	0.11	1.08	4.72	9.26	6.55	3.57	0.88	0.10	-5
LB	0.70	4.69	1.14	0.11	0.91	3.43	8.12	6.55	0	0.66	-	-
UB	1.13	5.74	1.75	0.14	1.60	4.80	12.86	9.60	10.99	1.11	-	-
Survivors	0.67	5.34	2.96	1.16	10.00	3.21	18.37	9.70	3.51 3.57?	0.84	0.13	0
LB	0.67	5.20	2.96	1.11	9.50	2.68	17.22	9.28	0	0.72	-	-
UB	0.79	5.34	3.59	1.24	10.00	3.21	19.59	9.85	10.99	0.92	-	-
Non-survivors	0.55	5.00	16.98	3.28	0.25	0.33	23.00	7.98	0.00	0.39	0.08	0
LB	-	-	-	-	-	0.22	-	-	-	0.29	-	-
UB	-	-	-	-	-	0.44	-	-	-	0.49	-	-
	$\tilde{\alpha}$	$log10(V_0)$	β	γ	$\delta/10^{-8}$	$\epsilon/10^{-1}$	$\eta/10^{-7}$	τ	$\theta/10^{-2}$	T_0	A_0	N
e:Mild Group	0.51	5.07	1.25	7.83	3.01	1.14	9.81	20.00	3.57	1.45	11.67	-10

LB	0.41	4.82	1.00	2.58	2.81	1.06	6.98	19.30	0	1.09	-	-
UB	0.60	5.76	1.44	7.83	4.16	1.22	9.81	20.00	10.99	1.81	-	-
i:Severe Group	0.16	5.32	0.52	0.02	6.31	1.56	30.93	14.61	1.29	0.89	11.53	-10
LB	0.15	2.63	0.50	0.02	5.93	1.28	30.60	13.58	0	0.60	-	-
UB	0.61	5.32	2.51	0.16	8.49	1.84	39.99	15.05	10.99	1.17	-	-

Table S5 Best fit and the minimums and maximums of parameters for survivors and non-survivors.

Uncertainty of S_{d0} was estimated by normal range of d-dimer[2]. The range of S_{h0} is estimated between 0 and the upper limit of the first data point of HSCT. The upper reference limit of HSCT in Fig.4 was from the averaged values in men and women[6].

Survivors	I_0	S_{d0}	S_{h0}	κ	λ	μ_d	ν_d	μ_h	ν_h
Best fit	6.40	0.25	0	1.63	1.64	0.04	0.40	0.24	0.41
LB	5.74	0	0.00	1.44	1.20	0.04	0.40	0.23	0.40
UB	8.35	0.5	2.5	3.00	3.00	0.07	0.40	0.25	0.43
Non-survivors	I_0	S_{d0}	S_{h0}	κ	λ	μ_d	ν_d	μ_h	ν_h
Best fit	10.73	0.25	0.00	1.63	0.00	0.08	0.00	0.37	0.00
LB	9.25	0	0.00	0.11	0.00	0.06	0.00	0.32	0.00
UB	12.83	0.50	95.25	2.12	0.02	0.11	0.00	1.00	0.37

Table S6 Constraints of input parameters for each case.

<table>
<tr><th>Patient ID</th><th>$\tilde{\alpha}$</th><th>$log10(V_0)$</th><th>β</th><th>γ</th><th>$\delta/10^{-8}$</th><th>$\epsilon/10^{-1}$</th><th>$\eta/10^{-8}$</th><th>τ</th><th>$\theta/10^{-2}$</th></tr>
<tr><td>a:908</td><td rowspan="3">0.1
2.5</td><td rowspan="3">1
8</td><td rowspan="2">1
5</td><td rowspan="5">0.1
5</td><td>0.01
5</td><td rowspan="2">1.14</td><td>0.02
5</td><td rowspan="2">5
20</td><td rowspan="2">3.57</td></tr>
<tr><td>b:904</td></tr>
<tr><td>c:901</td><td>0.01
50</td><td>0.02
100</td></tr>
<tr><td>f:902</td><td rowspan="2">1
10</td><td rowspan="2">0.01
5</td><td>1.40</td><td rowspan="2">0.02
5</td><td rowspan="3">1
20</td><td>5.11</td></tr>
<tr><td>g:910</td><td>0.33</td><td>5.49</td></tr>
<tr><td>h:916</td><td>0.7</td><td>2</td><td>3</td><td>0.15</td><td>1.40</td><td>0.4
5</td><td>3.57</td></tr>
<tr><td>2a:P1</td><td rowspan="2">0.1
2.5</td><td rowspan="2">1
8</td><td rowspan="2">1
10</td><td rowspan="2">0.1
5</td><td rowspan="2">0.01
5</td><td>1.14</td><td rowspan="2">0.02
20</td><td rowspan="2">5
25</td><td>1.65</td></tr>
<tr><td>2b:P3</td><td>0.30
0.90</td><td>2.03</td></tr>
</table>

d:P4				0.1 50		4.10 10.50			3.57
2c:P5	0.5 1.5		0.5 2	0.05 0.15	0.1 2.5	1 8	1 16	1 10	3.57
Survivors	0.1 2.5		1 5	0.1 5	1 10	1 5	0.02 20	5 20	3.51
Non-survivors	0.55	5	16.98	0.5 8	0.25	0.33	23	1 15	0.00
	$\tilde{\alpha}$	$log10(V_0)$	β	γ	$\delta/10^{-8}$	$\epsilon/10^{-1}$	$\eta/10^{-7}$	τ	$\theta/10^{-2}$
e:Mild Group	0.1 2.5	1 8	1 5	1 10	0.1 5	1.14	1 10	5 20	3.57
i:Severe Group			0.5 5	0.002 1	1 10	1.56	10 40		1.29

Table S7 Initial guess of parameters for each case.

Patient ID	$\tilde{\alpha}$	$log10(V_0)$	β	γ	δ $/10^{-8}$	ϵ $/10^{-1}$	η $/10^{-8}$	τ	θ $/10^{-2}$	T_0	A_0	N
a:908	0.80	6.00	2.00	0.80	0.07	1.14	0.16	8.00	3.57	1.45	0.11	-10
b:904	0.80	6.00	1.60	1.00	0.02	1.14	0.03	15.00	3.57	1.45	0.08	-10
c:901	0.50	4.00	1.40	0.50	30.00	1.14	70.00	15.00	3.57	1.45	0.06	-10
f:902	1.00	1.50	4.50	1.12	0.50	1.40	1.80	4.50	5.11	1.06	0.11	-10
g:910	1.00	2.00	6.00	2.40	0.18	0.33	0.95	6.00	5.49	0.64	0.11	-10
h:916	0.70	2.00	3.00	2.50	0.15	1.40	0.50	7.50	3.57	1.06	0.08	-10
2a:P1	1.00	4.00	4.92	0.30	0.59	1.14	11.00	10.00	1.65	1.74	0.30	-5
2b:P3	1.30	7.00	4.58	2.00	0.01	0.60	0.03	18.00	2.03	0.90	0.16	-5
d:P4	1.60	5.00	3.06	1.20	0.35	4.10	1.20	14.00	3.57	1.11	0.42	-5
2c:P5	0.80	4.00	1.10	0.09	0.29	4.70	4.00	3.50	3.57	0.88	0.10	-5
Survivor-s	1.00	5.00	2.60	0.90	4.00	0.15	9.00	9.50	3.57	0.84	0.13	0
Non-survivors	0.55	5.00	16.98	4.00	0.25	0.33	23.00	8.00	0.00	0.39	0.08	0
	$\tilde{\alpha}$	$log10(V_0)$	β	γ	δ $/10^{-8}$	ϵ $/10^{-1}$	η $/10^{-7}$	τ	θ $/10^{-2}$	T_0	A_0	N
e:Mild Group	0.86	4.00	2.51	1.00	1.00	1.14	1.00	10.00	4.57	1.45	11.67	-10
i:Severe Group	0.3	5.8	1.20	0.01	6	1.56	27	10.00	1.29	0.89	11.53	-10

Table S8 Upper and lower bounds for constraints of parameters to be varied and initial guesses for best fits of survivors and non-survivors. "-" means the parameter is fixed during the fit.

	I_0	S_{d0}	S_{h0}	κ	λ	μ_d	ν_d	μ_h	ν_h
Survivors	-	-	-	0 3	0 3	0 1	0.4 0.6	0 1	0.4 0.6
Initial guess	6.40	0.25	0	1.80	2.32	0.04	0.40	0.25	0.42
	I_0	S_{d0}	S_{h0}	κ	λ	μ_d	ν_d	μ_h	ν_h
Non-survivors	-	-	-	0 3	0 3	0 1	0 1	0 1	0 1
Initial guess	11.73	0.25	0	1.82	0.00	0.085	0.00	0.38	0.00

References

1. Tan, W. *et al.* Viral Kinetics and Antibody Responses in Patients with COVID-19. *medRxiv* 2020.03.24.20042382 (2020). doi:10.1101/2020.03.24.20042382
2. Zhang, X. *et al.* Viral and host factors related to the clinical outcome of COVID-19. *Nature* **583**, 437–440 (2020).
3. To, K. K.-W. *et al.* Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet. Infect. Dis.* **20**, 565–574 (2020).
4. Lescure, F. X. *et al.* Clinical and virological data of the first cases of COVID-19 in Europe: a case series. *Lancet Infect. Dis.* **20**, 697–706 (2020).
5. Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054–1062 (2020).
6. Stelzle, D. *et al.* High-sensitivity cardiac troponin I and risk of heart failure in patients with suspected acute coronary syndrome: a cohort study. *Eur. Hear. J. - Qual. Care Clin. Outcomes* **4**, 36–42 (2018).